Non Small Cell Lung CancerMetLungNCT01647867
Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers
A study testing Met analysis on tissue and blood in people with Non Small Cell Lung Cancer, run by Centre Oscar Lambret at 2 sites in France.
Trial summary
Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer
- What is being tested?
- Met analysis on tissue and blood
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 2 sitesFrance
- Study dates
- 27 Aug 2012to Jul 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with non small cell lung cancer (NSCLC)
- Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
- Treatment naive patient for metastatic NSCLC
- Patients with or without neoadjuvant therapy for localized NSCLC
- Male or female patients aged ≥ 18 years
- Patient registered with the social security system
- Having signed a written Informed Consent
Who cannot join
- Malignant tumors which are not carcinoma
- Small-cell malignant tumors
- Secondary bronchial lesions
- Revision surgery
- Pregnant or breastfeeding women
- Patient under guardianship or tutorship
- Previous cancer
Trial locations and contacts
2 sites in 1 country.
France2 sites
Centre Hospitalier Régional et Universitaire
Lille, 59 037
Oscar Lambret Center
Lille, 59020
About this study
Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.
Read the detailed description
- Patient information and collection of signed inform consent
- Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
- Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
- Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
- Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
- Selection of blocks of interest and preparation of tumor samples
- Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
- Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
- Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille
- Conditions
- Non Small Cell Lung Cancer
- Being tested
- Met analysis on tissue and blood
- Keywords
- Met fragments expression
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Met analysis on tissue and bloodOther
10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
| Study group | Role | What they receive |
|---|---|---|
| Met analysis | Experimental | Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test Receives: Other: Met analysis on tissue and blood |
What is being measured
The primary outcome is the main question the study is designed to answer.
Expression and localization of Met C-terminal active fragments in NSCLC
Western Blot and immunohistochemistry
Measured: baseline
Secondary outcomes (3)
Evaluation of the activation of Met receptor
Activation of Met receptor by immunochemical analysis (Western Blot)
Measured: baseline
Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival
Relationships between Met receptor expression and sex, TNM, EGFR status, histology, smoking status, survival
Measured: baseline
Expression in plasma of N-terminal Met fragments
ELISA test
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2012 (estimated)
- Study start27 Aug 2012
- Primary completionJul 2015
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Oscar Lambret
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eric DANSIN, MD, Study director, Centre Oscar LambretDavid TULASNE, PhD, Study director, Institute of Biology of Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01647867
- Sponsor's protocol ID
- MetLung - 1204
- Other IDs
- 2012-A00468-35
- Acronym
- MetLung
- Status last verified
- Mar 2026
- First submitted
- 17 Jul 2012
- Last updated
- 13 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers
- ClinicalTrials.gov ID
- NCT01647867
- Acronym / sponsor ID
- MetLung / MetLung - 1204
- Conditions
- Non Small Cell Lung Cancer
- Keywords
- Met fragments expression
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Centre Oscar LambretUniversity, hospital or other
- Study start
- 27 Aug 2012 (actual)
- Primary completion
- Jul 2015 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 24 Jul 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.
Detailed description
- Patient information and collection of signed inform consent
- Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
- Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
- Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
- Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
- Selection of blocks of interest and preparation of tumor samples
- Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
- Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
- Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Met analysis | Experimental | Other: Met analysis on tissue and bloodMet analysis on tissue and blood Western Blot Immunohistochemistry ELISA test |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with non small cell lung cancer (NSCLC)
- Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
- Treatment naive patient for metastatic NSCLC
- Patients with or without neoadjuvant therapy for localized NSCLC
- Male or female patients aged ≥ 18 years
Key exclusion criteria (7 listed)
- Malignant tumors which are not carcinoma
- Small-cell malignant tumors
- Secondary bronchial lesions
- Revision surgery
- Pregnant or breastfeeding women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Met analysis on tissue and blood10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease | Other | Met analysis |
Primary outcome
Expression and localization of Met C-terminal active fragments in NSCLC
Time frame: baseline
Western Blot and immunohistochemistry
3 secondary outcomes
Evaluation of the activation of Met receptor
Time frame: baseline
Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival
Time frame: baseline
Expression in plasma of N-terminal Met fragments
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric DANSIN, MD study director
Centre Oscar Lambret
David TULASNE, PhD study director
Institute of Biology of Lille
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Met analysis on tissue and blood in people with Non Small Cell Lung Cancer, run by Centre Oscar Lambret at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Expression and localization of Met C-terminal active fragments in NSCLC (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.